Ticker

No recent analyst price targets found for PORT.

Latest News for PORT

GondolaBio Announces Positive Phase 2a Results Demonstrating 79% Plasma Protoporphyrin IX Reduction and Disease-Modifying Potential of PORT-77 for Erythropoietic Protoporphyria

PALO ALTO, Calif.--(BUSINESS WIRE)--GondolaBio, a clinical-stage biopharmaceutical company developing novel medicines for patients living with genetic diseases, on behalf of its affiliate Portal Therapeutics, today announced positive data from its Phase 2a GATEWAY trial of PORT-77 in patients with erythropoietic protoporphyria (EPP). PORT-77 is a novel investigational oral, small molecule ABCG2 inhibitor designed to…

Business Wire • Jun 22, 2026
ROYAL CARIBBEAN GROUP ANNOUNCES EXIT GLACIER GREENHOUSES AS 2026 'PORT PARTNERS' SMALL BUSINESS ACCELERATOR AWARDEE IN SEWARD, ALASKA

The comprehensive program supporting local entrepreneurs culminated in a pitch competition spotlighting local innovation and economic growth SEWARD, Alaska, June 9, 2026 /PRNewswire/ -- Royal Caribbean Group (NYSE: RCL), a global vacation leader, today announced Exit Glacier Greenhouses, pioneered by Sydney Singer, as the recipient of its inaugural Port Partners Small Business Accelerator Award, recognizing the…

PRNewsWire • Jun 9, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for PORT.

No House trades found for PORT.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top